Copiktra and Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir Extended-Release Tablets
Determining the interaction of Copiktra and Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir Extended-Release Tablets and the possibility of their joint administration.
In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.
Consumer:Ritonavir may significantly increase the blood levels of duvelisib. This may increase the risk and/or severity of serious side effects such as diarrhea, inflammation of the intestine or lungs, low white blood cell and platelet counts, infections, skin reactions, and liver problems. Talk to your doctor if you have any questions or concerns. Your doctor may be able to prescribe alternatives that do not interact, or you may need a dose adjustment or more frequent monitoring to safely use both medications. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Professional:ADJUST DOSE: Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of duvelisib, which is primarily metabolized by the isoenzyme. When a single 10 mg oral dose of duvelisib was coadministered with the potent CYP450 3A4 inhibitor ketoconazole (200 mg twice daily for 5 days) in 16 healthy study subjects, duvelisib peak plasma concentration (Cmax) and systemic exposure (AUC) increased by 1.7- and 4-fold, respectively. Based on physiologically-based pharmacokinetic (PBPK) modeling and simulation, the increase in duvelisib exposure is estimated to be approximately 2-fold at steady state during coadministration with potent CYP450 3A4 inhibitors.
MANAGEMENT: The dosage of duvelisib should be reduced to 15 mg twice daily when used with potent CYP450 3A4 inhibitors. Patients should be closely monitored for the development of toxicities such as diarrhea, colitis, neutropenia, thrombocytopenia, pneumonitis, infections, cutaneous reactions and hepatotoxicity, and the dosing adjusted or discontinued in accordance with the duvelisib product labeling.
- "Product Information. Copiktra (duvelisib)." Verastem, Inc., Needham, MA.
Generic Name: dasabuvir / ombitasvir / paritaprevir / ritonavir
Brand name: Viekira XR, Viekira Pak
Synonyms: Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Copiktra-Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir Tablets
- Copiktra-Omeclamox-Pak
- Copiktra-Omega-3 Fatty Acid Capsules
- Copiktra-Omega-3 Fatty Acids
- Copiktra-Omega-3 polyunsaturated fatty acids
- Copiktra-Omega-3-acid ethyl esters
- Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir Extended-Release Tablets-CoQ10 coenzyme Q-10
- Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir Extended-Release Tablets-Coral Calcium
- Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir Extended-Release Tablets-Cordarone
- Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir Extended-Release Tablets-Cordarone injection
- Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir Extended-Release Tablets-Cordarone IV Intravenous
- Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir Extended-Release Tablets-Cordran